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ABSTRACT
Objectives Mortality and worsening of organ function 
are desirable endpoints for clinical trials in systemic 
sclerosis (ssc). The aim of this study was to identify 
factors that allow enrichment of patients with these 
endpoints, in a population of patients from the european 
scleroderma Trials and Research group database.
Methods inclusion criteria were diagnosis of diffuse 
ssc and follow-up over 12±3 months. Disease 
worsening/organ progression was fulfilled if any of the 
following events occurred: new renal crisis; decrease of 
lung or heart function; new echocardiography-suspected 
pulmonary hypertension or death. in total, 42 clinical 
parameters were chosen as predictors for the analysis 
by using (1) imputation of missing data on the basis of 
multivariate imputation and (2) least absolute shrinkage 
and selection operator regression.
Results Of 1451 patients meeting the inclusion 
criteria, 706 had complete data on outcome parameters 
and were included in the analysis. Of the 42 outcome 
predictors, eight remained in the final regression model. 
There was substantial evidence for a strong association 
between disease progression and age, active digital 
ulcer (DU), lung fibrosis, muscle weakness and elevated 
C-reactive protein (CRP) level. active DU, CRP elevation, 
lung fibrosis and muscle weakness were also associated 
with a significantly shorter time to disease progression. 
a bootstrap validation step with 10 000 repetitions 
successfully validated the model.
Conclusions The use of the predictive factors presented 
here could enable cohort enrichment with patients at risk 
for overall disease worsening in ssc clinical trials.
InTROduCTIOn
Systemic sclerosis (SSc), a rheumatic disease char-
acterised by autoimmunity, tissue fibrosis and 
vasculopathy, has a high mortality rate compared 
with other rheumatic diseases.1 2 Mortality in 
SSc is the result of organ involvement, with lung 
disease (either interstitial lung disease or pulmo-
nary arterial hypertension (PAH)) being the most 
prominent risk factor for death.3 Skin fibrosis is a 
hallmark of SSc and is easily measurable in a stan-
dardised manner using the modified Rodnan skin 
score (mRSS), which has good inter-rater and intra 
rater variability.4–7 The mRSS also correlates with 
organ involvement; the rate of progression of skin 
thickness can predict early mortality in patients 
with diffuse SSc (dcSSc), while early worsening 
of mRSS (within 12 months) is associated with 
poorer survival and increased disease progres-
sion8 9 Consequently, the mRSS is widely used 
as a primary outcome parameter in clinical trials 
of patients with dcSSc or as a part of composite 
indices.9–12 However, skin fibrosis is only a surro-
gate marker for overall disease progression,13 
and the use of more relevant endpoints, such as 
worsening organ function or death, is desirable 
for clinical trials and is increasingly requested 
by regulatory authorities. One methodological 
limitation is that these events are relatively rare 
in unselected patients. In clinical trials of dcSSc, 
enriching a dataset with these endpoints requires 
identification of predictive factors associated with 
organ worsening or death; these factors can then 
be considered as inclusion criteria for clinical trial 
designs with enriched patient populations. We 
Key messages
What is already known about this subject?
 ► Capturing the complexity and heterogeneity of 
systemic sclerosis in clinical trials is difficult.
 ► The widely used modified Rodnan skin score 
failed in recent clinical trials as a surrogate 
parameter for universal disease progression. 
Using worsening of organ involvement as 
a study endpoint is impeded by its relative 
sparsity.
What does this study add?
 ► We have identified factors that are associated 
with disease progression and lead to organ 
failure.
How might this impact on clinical practice or 
future developments?
 ► The factors identified here could be used to 
select patients at risk of progressive organ 
involvement for clinical trials.
 ► Identifying patients at risk also has implications 
for clinical care.
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aimed to identify predictive factors for disease worsening and 
death in patients with dcSSc by analysing data from the large 
European Scleroderma Trials and Research (EUSTAR) group 
database.
MeTHOdS
Patients and study design
This study used prospectively collected data from the EUSTAR 
database. The structure of the EUSTAR database and minimum 
essential dataset have been described previously.14 15
Data from patients with dcSSc (as defined by LeRoy et al)16 
were included if they had a visit in 2009 or later (defined as 
the baseline visit) and either a follow-up visit or death within 
12±3 months after baseline. Twelve months was chosen as the 
primary analysis point, as this reflects the usual study duration 
of SSc trials targeting fibrosis.
definition of disease worsening
An expert group (YA, MM-C, CPD, OD, JP) defined the 
combined endpoint of disease worsening, which was agreed 
on by nominal group technique. A patient was considered to 
have organ worsening if he or she fulfilled any of the following 
criteria within 12±3 months of the baseline visit: new-onset 
renal crisis; decrease in forced vital capacity (FVC)≥10%; 
new left ventricular ejection fraction (LVEF)<45% or decrease 
in LVEF by>10% for patients with baseline LVEF<45%; 
new-onset echocardiography-suspected pulmonary hyperten-
sion (PH) (as defined by the treating physician); or death. Vari-
able definitions, recoding of variables and handling of missing 
values are described in the online supplementary appendix.
Statistical analysis
For variables with >10% missing data, the missing not at 
random (MNAR) assumption was explored where possible, 
but the analyses did not support the assumption of MNAR, 
instead random missingness was assumed (see online supple-
mentary appendix for more details).
Missing data were imputed on the basis of multiple imputa-
tion (MI) using the R package mice. For the imputation model, 
all 42 variables from the full model, including the dependent 
variable ‘disease worsening’, were included. With the function 
quickpred, predictors were automatically selected (1) with 
an absolute correlation with the target variable of ≥0.2 and 
(2) with a proportion of usable cases (ie, cases with missing 
data on the target variable that had observed values on the 
predictor) of ≥0.25. The order of variable imputation was 
defined according to the number of missing cases. Depending 
on the scale of the target variable, MI was performed using 
either linear regression ( norm. nob), logistic regression (logreg) 
or polytomous, ordered regression (polr) for factors with more 
than two levels. Based on the fraction of missing informa-
tion,17 100 imputed datasets were generated. Further details 
of statistical analysis are described in the online supplementary 
appendix.
Patient and public involvement
This was a retrospective study using a registry with patient 
data from different primary investigation sites. However, 
neither direct patients nor the public were involved. Study 
results will be disseminated within patient communities via 
the Federation of European Scleroderma Associations and its 
patient congresses.
ReSulTS
Baseline characteristics
In total, 1451 patients met the inclusion criteria at the time 
of data extraction (10 February 2016). Of these, 706 had 
data on the presence of the combined endpoints available and 
were included in the analysis. Patient baseline characteristics 
are shown in table 1, with a comparison between the 706 
included patients and the 745 excluded patients shown in the 
online supplementary table S2. There was no major difference 
between these groups, although numerically, patients without 
missing data had a slightly higher disease duration and more 
renal crises but less frequent active disease. Hence, there was 
no major selection bias. However, a bias based on unmeasured 
variables cannot be excluded.
Predictive factors for disease worsening
Of 706 patients with available data, 228 (32.3%) fulfilled the 
pre-defined criteria for disease worsening within 12±3 months 
of the baseline visit. The most common forms of disease wors-
ening were deterioration of FVC and death (table 2). Renal crisis 
and worsening of LVEF were rare.
Figure 1 presents the multiple imputation—least absolute 
shrinkage and selection operator (MI-LASSO) regression coeffi-
cients based on averages across 100 imputed datasets, presented 
on a logarithmic OR scale evaluated for 24 varying penalisa-
tion factors (lambda). The regression coefficient estimates at 
each selected penalisation factor indicate the extent to which 
they contribute to a change in the probability of disease progres-
sion in terms of ORs in comparison to the population mean. 
The smaller the lambda, the larger the penalisation; therefore, 
average regression coefficients are shrunk towards zero. The 
model with the smallest Bayesian Information Criterion (BIC) 
was chosen as the final model. If a regression coefficient was 
shrunk to zero, the predictor variable was no longer retained in 
the final model.
Table 3 shows the final model, with OR and 95% CI based on 
all 100 imputed datasets. All ORs were>1 and, therefore, posi-
tively associated with disease worsening. There was substantial 
evidence for a strong association between disease progression 
and age, active digital ulcers (DUs), C-reactive protein (CRP) 
elevation, lung fibrosis and muscle weakness. The p values 
for pericardial effusion, proteinuria and significant dyspnoea 
suggest only weak or very weak evidence for an association with 
disease worsening.
As muscle weakness was a non-objectively defined, patient-re-
ported parameter, we aimed to further characterise patients 
with this symptom. In patients defined as having muscle weak-
ness, the frequency of creatine kinase (CK) elevation was higher 
than in those without weakness (19.9% (n=31/156) vs 6.2% 
(n=32/513); p<0.0001 by χ2 test); a higher frequency of gastro-
intestinal symptoms (39.0% (64/164) vs 21.1% (113/535); 
p<0.0001 by χ2 test); and a higher number of deaths (25.0% 
(41/164) vs 8.9% (48/537); p<0.0001 by χ2 test) were also 
observed in those with muscle weakness compared with those 
without.
Applicability and feasibility of the predictors retained in the 
final model
To illustrate the impact of the final model on the probability of 
increasing the number of patients with worsening organ func-
tion in a given selection of patients, we calculated the outcome 
probabilities for combinations of risk factors from the final 
model in the 706 study patients (table 4). As suggested by the 
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Table 1 Clinical and demographic characteristics of the 706 
patients from the EUSTAR database included in the analysis
Characteristics
Patients 
(n=706)
Available data 
(% patients)
Demographic
Male sex 172 (24.4) 100
Age, mean±SD 52.9±12.9 100
Disease duration, months (mean±SD) 101.1±94.0 94.1
Body weight, kg (mean±SD) 64.6±13.4 97.2
Laboratory parameters
ANA positive 657 (94.4) 98.6
ACA positive 48 (7.1) 96.3
Anti-Scl70 positive 414 (60.2) 97.5
Anti-U1RNP positive 27 (4.7) 81.3
Creatine kinase elevation 64 (9.5) 95.2
Proteinuria 57 (8.4) 95.6
Hypocomplementaemia 39 (6.3) 88.1
ESR>20 mm/1 hour, mean±SD 25.3±20.6 94.5
CRP elevation 190 (27.7) 97.0
Vascular
Raynaud’s present 683 (96.7) 100
DU ever 266 (38.1) 98.9
Active DU* 126 (18.1) 98.7
Scleroderma (puffy fingers) 303 (44.2) 97.2
Worsening of finger vascularisation within the 
last month
162 (23.3) 98.3
Musculoskeletal
Tendon friction rubs 89 (12.8) 98.3
Joint synovitis 108 (15.4) 99.3
Joint contractures 310 (44.4) 98.9
Muscle weakness 164 (23.4) 99.3
Skin
mRSS, mean±SD 14.2±9.1 93.2
Worsening of skin changes within the last 
month
141 (20.3) 98.3
Skin progression rate, mean±SD 0.6±1.7 88.2
Cardiopulmonary
Arterial hypertension 154 (21.9) 99.6
Pericardial effusion 58 (8.9) 92.5
Echocardiography-suspected PH 113 (16.3) 98.0
Conduction blocks 104 (15.6) 94.2
Abnormal diastolic function 170 (25.0) 96.2
Lung fibrosis† 131 (19.7) 94.3
Significant dyspnoea 91 (13.2) 97.7
DLCO, %predicted (mean±SD) 64.1±20.2 94.1
FVC, %predicted (mean±SD) 86.4±21.3 96.5
FEV1, %predicted (mean±SD) 85.0±18.7 78.3
TLC, %predicted (mean±SD) 84.2±19.9 66.1
LVEF, %predicted (mean±SD) 61.7±7.0 96.5
Gastrointestinal
Oesophageal symptoms 455 (64.5) 99.9
Stomach symptoms 192 (27.4) 99.3
Intestinal symptoms 177 (25.2) 99.3
Kidney
Renal crisis 34 (4.8) 99.4
Disease activity
Active disease‡ 191 (30.7) 88.1
Continued
Characteristics
Patients 
(n=706)
Available data 
(% patients)
Data are n (%) unless otherwise stated. (Percentages with characteristics were 
calculated from numbers of patients with data available).
Clinical manifestations were defined according to the EUSTAR definitions.15
Presence of significant dyspnoea was based on the judgement of the treating 
physician.
*Active DUs was a composite endpoint that was considered positive if either DU 
(from the minimal essential dataset) or digital gangrene was present.
†Lung fibrosis was defined as FVC<60% or FVC<70% and presence of lung fibrosis 
on high-resolution computed tomography.
‡Active disease was defined as score >3 calculated according to the EScSG disease 
activity indices for SSc.38
ACA, anti-centromere antibody; ANA, anti-nuclear antibody; CRP, C-reactive protein; 
DLCO, diffusion capacity of the lung for carbon monoxide; DU, digital ulcer; ESR, 
erythrocyte sedimentation rate;EScSG, European Scleroderma Study Group; EUSTAR, 
European Scleroderma Trials and Research; FEV1, forced expiratory volume after 1 
s; FVC, forced vital capacity; LVEF, left ventricular ejection fraction;mRSS, modified 
Rodnan skin score; PH, pulmonary hypertension; TLC, total lung capacity.
Table 1 Continued
Table 2 Frequency of disease worsening
disease worsening Yes no Missing
Any* 228 (32.3) 478 (67.7) —
Worsening FVC 103 (14.6) 514 (72.8) 89 (12.6)
Death within 12 (±3) months 92 (13.0) 614 (87)
New echocardiography-suspected PH 37 (5.2) 582 (82.4) 87 (12.3)
New renal crisis 7 (1.0) 613 (86.8) 86 (12.2)
Worsening LVEF 5 (0.7) 614 (87.0) 87 (12.3)
Data are n (%).
*Patients were considered to have disease worsening if death occurred within 12±3 
months after baseline or if worsening was present for any of the other components.
FVC, forced vital capacity; LVEF, left ventricular ejection fraction; PH, pulmonary 
hypertension.
high ORs for lung fibrosis and CRP elevation (see table 3), these 
two factors alone increased the probability for an event during 
the observation time to 52.0% in patients aged 60 years and 
57.9% in patients aged 70 years (table 4) compared with 32.2% 
for the overall study population. If patients had lung fibrosis, 
muscle weakness, DU and CRP elevation, the probability for an 
event was 74.5% at 60 years and 78.8% at 70 years (table 4). 
However, depending on the number of predictors included, the 
number of selected patients decreased, for example, the optimal 
combination for maximum enrichment left only eight patients 
who had lung fibrosis, muscle weakness, CRP elevation and 
present DUs in our study population (table 4).
Impact of predictors from the final model during long-term 
observation
To evaluate the impact of the predictors retained in the final 
model on survival, we additionally calculated long-term event-
free survival curves for patients with SSc with and without risk 
factors. Specifically, we tested the most clinically feasible combi-
nations of increased CRP and presence of lung fibrosis or DU. 
These combinations showed a significantly worse event-free 
survival with the risk factors present (figure 2). With the pres-
ence of lung fibrosis and elevated CRP, the median time to an 
outcome event was 1.53 years versus 4.48 years for patients 
without any risk factors, that is, active DU, CRP elevation, signif-
icant dyspnoea, lung fibrosis, muscle weakness, pericardial effu-
sion or proteinuria (figure 2A; p<0.001 by log-rank test). Active 
DU and elevated CRP shortened the median time to an outcome 
event from 4.48 years to 1.82 years (figure 2B; p<0.001 by 
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Figure 1 Average regression coefficients across 100 imputations 
plotted against the penalisation parameter, lambda. The vertical dashed 
line represents the selected model chosen as it had the smallest 
Bayesian information criterion. Traces in colour are those of the 
regression coefficients (and hence predictor variables) that remained in 
the final model. Traces for excluded regression coefficients are plotted in 
black and are not specified in the legend. CRP, C-reactive protein.
Table 3 Final regression model for disease worsening
p Value OR 95% CI
Age (years) 0.001 1.02 1.01 to 1.04
lung fibrosis 0.0004 2.21 1.43 to 3.41
CRP elevation 0.002 1.80 1.23 to 2.63
Muscle weakness 0.015 1.64 1.10 to 2.45
Active du 0.026 1.64 1.06 to 2.54
Proteinuria 0.064 1.75 0.97 to 3.16
Pericardial effusion 0.098 1.65 0.91 to 2.97
Significant dyspnoea 0.491 1.20 0.72 to 2.00
Parameters in bold had strong evidence for a significant association with disease 
progression in the final model.
CRP, C-reactive protein; DU, digital ulcer.
Table 4 Probability (%) of disease worsening for combinations of 
predictors in study population (n=706)
Other risk factors*
Age Patient 
numbers†60 years 65 years 70 years
Lung fibrosis 37.5 40.4 43.3 131/666
Lung fibrosis and CRP elevation 52.0 55.0 57.9 47/650
Active DU 30.9 33.5 36.1 126/697
Lung fibrosis and active DU 49.7 52.6 55.6 31/662
Muscle weakness 30.9 33.5 36.2 164/701
Lung fibrosis, muscle weakness 
and active DU
61.8 64.6 67.3 16/660
Lung fibrosis, muscle weakness,
CRP elevation and active DU
74.5 76.7 78.8 8/646
*Predictors not specified in each row are set to zero.
†Patient numbers irrespective of age that fulfil the criteria within the whole study 
population.
CRP, C-reactive protein; DU, digital ulcer.
log-rank test). The additional analysis of four risk factors on 
their own showed that each (active DU, raised CRP, presence of 
lung fibrosis and muscle weakness) was associated with a signifi-
cantly increased incidence of outcome events during follow-up 
as well as in combination (each p<0.001 by log-rank test; see 
online supplementary figure S5).
Model validation
A bootstrap with 10 000 repetitions was used to validate the 
final model chosen by the BIC. The C-index, which is identical 
to the area under the receiver operating characteristic, is a good 
measure to estimate discrimination. This in turn refers to the 
ability of the model to separate patients with and without the 
outcome event. The final model had a C-index of 0.711, which 
was 0.705 at validation, indicating good calibration (ie, agree-
ment between actual and predicted probabilities) (see online 
supplementary figure S1).
dISCuSSIOn
By using a novel statistical approach to analyse data from a 
clinical registry, we successfully identified predictors of severe 
disease worsening—defined as organ failure within a period 
of 12±3 months—in patients with dcSSc. Based on our 
logistic regression model, we showed that the probability of a 
60-year-old patient with lung fibrosis, DU, muscle weakness and 
CRP elevation developing disease worsening within the obser-
vation period increases to 74.5% compared with 32.2% for the 
whole study population. The predictive factors of age, presence 
of DU, lung fibrosis, CRP elevation and muscle weakness repre-
sent important aspects of the disease and also correspond to the 
key characteristic features of vasculopathy (DU), autoimmunity/
inflammation (CRP elevation) and tissue fibrosis (lung fibrosis). 
In addition to being predictive in our model for progression of 
disease after 12±3 months, the presence of DU, lung fibrosis, 
CRP elevation and muscle weakness could also predict, alone 
or in combination, disease progression over a longer period of 
time (up to 6 years after the baseline visit). This confirms the 
role of CRP elevation as an indicator of active disease and its 
potential relevance as an inclusion criterion in trials.18–21 The 
data also support the notion that the presence of muscle weak-
ness may include patients with overt myositis/myopathy, as well 
as patients with gastrointestinal problems being more likely to 
have malnutrition and consecutive muscle weakness.
DUs were identified in a previous EUSTAR study as a risk factor 
for cardiovascular worsening and mortality.22 Lung involvement 
in SSc is well known,3 and this is reflected in the high incidence 
of worsening FVC (14.6%) in the present study, while develop-
ment of PH was the third most frequent event (5.2%) leading 
to disease worsening. The relatively high frequency of the FVC 
endpoint corresponds to the high OR for lung fibrosis in the 
final model. The discriminative value of a 10% decline in FVC 
has recently been confirmed by another report showing that this 
magnitude of decline is associated with increased mortality.23 The 
percentage of patients with a significant FVC decline is similar 
to the patients with SSc receiving placebo from the Scleroderma 
Lung Study I/II analysis (approximately 15%).24 The percentage 
of patients developing new echocardiography-suspected PH in 
our analysis was slightly higher than in the at-risk population 
included in the Pulmonary Hypertension Assessment and Recog-
nition of Outcomes in Scleroderma registry (7% at 2 years)25 
and much higher than in unselected patients, where the annual 
incidence is approximately 1.4%–1.5%.26 27 This is most likely 
due to a combination of patient selection in our cohort and use 
of an echocardiography-suspected PH definition that was not 
strictly based on right heart catheterisation data but based on 
assessment by the treating physician. The mortality rate within 
12±3 months among patients with dcSSc in the present study 
(13%) was relatively high compared with earlier reports from 
the EUSTAR database (5-year mortality from diagnosis in all 
patients with SSc of 11%)28 but also surpasses the 13% early 
mortality (within 3 years) recently reported in a multinational 
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Figure 2 Event-free survival in patients with SSc depending on risk 
factors for progression of organ damage. (A) Event-free survival of 
patients with SSc fulfilling the inclusion criteria (diffuse SSc, death or 
at least one follow-up visit earliest at 12±3 months after baseline visit 
in 2009 or later) with risk factors (elevated CRP and presence of lung 
fibrosis) versus no risk factors (active DU, CRP elevation, significant 
dyspnoea, lung fibrosis, muscle weakness, pericardial effusion and 
proteinuria). The median survival time for patients with and without risk 
factors was 1.53 years (95% CI 1.13 to 1.99) and 4.48 years (95% CI 
3.70 to 4.97), respectively. The log-rank test was significant (p<0.001). 
(B) Event-free survival of patients with SSc fulfilling the inclusion criteria 
with risk factors (elevated CRP and active DU) versus no risk factors. 
The median survival time for patients with and without risk factors was 
1.82 years (95% CI 1.23 to 2.47) and 4.48 (95% CI 3.70 to 4.97) years, 
respectively. The log-rank test was significant (p<0.001). CRP, C-reactive 
protein; DU, digital ulcer; LF, lung fibrosis; SSc, systemic sclerosis.
inception cohort.29 However, the cohort used in the present 
analysis was selected to include dcSSc only, and thus was prone 
to have more complications than a general SSc cohort. In addi-
tion, deaths in the present study were all-cause deaths and not 
limited to SSc-related causes, with 63.3% of deaths documented 
as SSc related. However, currently, there is no clear definition of 
SSc-related mortality.
Our study was designed to address two important limitations 
that are often encountered when searching for predictive factors 
in large datasets from patient registries. First, there is often a 
high incidence of missing data, and second there are limits to 
the number of potential predictive variables that can be included 
in the statistical model. Observations with missing data on any 
predictor variable will be eliminated in the process of ordinary 
logistic regression, so that only a ‘full dataset’ with valid data on 
all candidate predictor variables can be used in the final anal-
ysis. As patient registries such as EUSTAR depend on data input 
from many clinical centres, they typically have a certain amount 
of missing data. In addition, a low incidence of outcome events 
limits the number of predictive variables that can be used for the 
analysis, as the ratio of outcome events to predictor variables in 
the model should ideally be 1:10 or lower.30 The issue of missing 
data was addressed in our analysis by imputing missing data on 
the basis of MI. The issue of limited predictive variables was 
addressed by using LASSO, a different type of regression anal-
ysis that allows selection and reduction of predictor variables 
(‘shrinkage’).31
It is possible that collection of some variables in the EUSTAR 
database began only recently or changed their definition during 
the data collection period. For example, PH is now mainly 
recorded as PAH. While PAH is currently defined in EUSTAR 
by mean pulmonary arterial and wedge pressures measured 
during right heart catheterisation, when the registry was initi-
ated, PH was estimated by echocardiography. Hence, echocar-
diography-suspected PH in our study possibly overestimates 
true PAH. It seems likely that, as genuine PAH is strongly asso-
ciated with mortality in SSc, the 92 deaths (13%) include some 
deaths resulting from PAH. Despite these limitations, our novel 
approach to the data in the EUSTAR registry successfully iden-
tified clinical features that allow enrichment of patients with 
dcSSc with disease worsening defined by organ failure.
Enriching a recruitment for clinical trials for progression of 
organ damage is not the same as for disease worsening as defined 
by progression of skin fibrosis. Therefore, the predictive factors 
that allow selection of patients with a higher probability for future 
increase in mRSS—baseline mRSS, joint synovitis, age, gender, 
disease duration and CK elevation32—are different. mRSS is a 
validated marker of overall disease severity and progression; 
baseline mRSS predicts both worsening and improvement of skin 
fibrosis,33 progression of skin fibrosis within 1 year is associated 
with a decline in lung function and decreased survival, and skin 
progression rate and trajectories are linked to increased mortality 
and the risk of renal crisis.12 13 34 However, skin fibrosis remains 
a surrogate marker and is not a direct measure of overall disease 
morbidity and mortality. In addition, it did not perform well as a 
primary outcome measure in recent randomised controlled trials 
for SSc35–37 (while other secondary and exploratory endpoints 
such as FVC and patient-reported outcomes have shown prom-
ising trends), indicating that the mRSS has inefficient sensitivity 
to change according to morbidity.18
Clinical trial design in SSc is undergoing major changes in the 
selection of endpoints; it is likely that these will change from use 
of mRSS as the most common primary endpoint to other items 
or indices considering progression of organ involvement, overall 
disease progression and death. In addition to the endpoints used 
in this study, these could also encompass the mRSS or other 
outcomes including gastrointestinal involvement (weight loss), 
digital ischaemia, myopathy, disability and other features that 
have an impact on patients’ lives. So far, little information has 
been available about which patient cohorts could be used for 
these analyses to allow for enough events and to make these 
novel study designs possible. This study provides evidence-based 
information from the largest SSc database available worldwide 
regarding which patients are appropriate for inclusion in these 
clinical trials. Although self-reported muscle weakness is difficult 
to use in clinical trials, an increased CRP and the presence of 
lung fibrosis and DUs are feasible inclusion criteria for further 
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clinical trials. However, the selection of enrichment criteria for 
a clinical study must be balanced against feasibility of recruit-
ment and representation of a broader SSc population. Hence, 
this study provides key data to inform a novel study design that 
could likely be applied in the near future.
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